التفاصيل البيبلوغرافية
| العنوان: |
Expression of cell surface zinc transporter LIV1 in triple negative breast cancer is an indicator of poor prognosis and therapy failure. |
| المؤلفون: |
Saravanan, Roshni1 (AUTHOR), Balasubramanian, Vaishnavi1 (AUTHOR), Sundaram, Sandhya2 (AUTHOR), Dev, Bhawna3 (AUTHOR), Vittalraj, Pavithra2 (AUTHOR), Pitani, Ravi Shankar4 (AUTHOR), Shanmugasundaram, Gouthaman5 (AUTHOR), Rayala, Suresh Kumar6 (AUTHOR) rayala@iitm.ac.in, Venkatraman, Ganesh7 (AUTHOR) ganesh.v@vit.ac.in |
| المصدر: |
Journal of Cellular Physiology. Apr2024, Vol. 239 Issue 4, p1-11. 11p. |
| مصطلحات موضوعية: |
*TRIPLE-negative breast cancer, *PROGESTERONE receptors, *ZINC transporters, *EPIDERMAL growth factor, *SECONDARY primary cancer, *ESTROGEN receptors |
| الشركة/الكيان: |
UNITED States. Food & Drug Administration |
| مستخلص: |
Triple negative breast cancers (TNBC) are an aggressive molecular subtype of breast carcinoma (BC) identified by the lack of receptor expression for estrogen, progesterone, & human epidermal growth factor receptor‐2. Lack of tangible drug targets warrants further research in TNBC. LIV1, is a zinc (Zn) transporter known to be overexpressed in few cancer types including BCs. Recently, in the United States of America, FDA approved the use of a new drug targeting LIV1, antibody drug conjugate SGN‐LIV1A for treatment of TNBC patients. Though LIV1 also has a role in modulating immune cells by its differential transport of Zn, a correlation between the tumor cell expression of LIV1 and immune cell infiltrations were scantily reported. Further adequate baseline data on LIV1 expression in other populations have not been documented. Our objective was to screen a large Indian cohort of TNBC patient samples for LIV1, categorize the immune cell infiltration using CD4/CD8 expression and correlate the findings with therapy outcomes. Further, we also investigated for LIV1 expression in matched samples of primary & secondary tumors; pre & postchemotherapy in TNBC patients. Results showed an elevated expression of LIV1 in TNBC samples as compared to adjacent normal, the mean Q scores being 183.06 ± 6.39 and 120.78 ± 7.37 (p < 0.0001), respectively. Similarly, LIV1 levels were elevated in secondary tumors than primary & in patient samples postchemotherapy as compared to naïve. In the TNBC cohort, using automated method, cell morphology parameters were computed and analysis showed LIV1 levels were elevated in grade 3 TNBC samples presenting with altered cell morphology parameters namely cell size, cell perimeter, & nucleus size. Thus indicating LIV1 expressing TNBC samples portrayed an aggressive phenotype. Finally, TNBC patients with 3+ staining intensity showed poor survival (4.44 year) as compared to patients with 2+ LIV1 expression (5.47 year), emphasizing that LIV1 expression is a poor prognostic factor in TNBC. In conclusion, the study reports elevated expression of LIV1 in a large Indian TNBC cohort; high expression is a poor prognostic factor and correlated with aggressive disease and indicating the need for LIV1 targeted therapies. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
